OncoMatch/Clinical Trials/NCT04661020
CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Is NCT04661020 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies CD19 CAR-T cells for large b-cell lymphoma (lbcl).
Treatment: CD19 CAR-T cells — A Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 expression (positive)
Confirmed CD19 and CD20 postive expressions in lymphoma cells
Required: CD20 expression (positive)
Confirmed CD19 and CD20 postive expressions in lymphoma cells
Required: MYC rearrangement
high grade B-cell lymphoma (HGBL) with gene rearrangement of MYC and BCL2 and/or BCL6
Required: BCL2 rearrangement
high grade B-cell lymphoma (HGBL) with gene rearrangement of MYC and BCL2 and/or BCL6
Required: BCL6 rearrangement
high grade B-cell lymphoma (HGBL) with gene rearrangement of MYC and BCL2 and/or BCL6
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CAR-T cell therapy
Previously treated with any CAR-T cell product or other genetically modified T cell therapies
Lab requirements
Kidney function
creatinine ≤ 176.8 umol/l
Liver function
total bilirubin ≤ 51 umol/l, alt and ast ≤ 3 times of upper limit of normal
Cardiac function
echocardiogram shows left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04661020 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Does this trial require CD20?
Yes, CD20 expression is a required biomarker for enrollment.
Does this trial require MYC?
Yes, MYC rearrangement is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify